$GNLN

Marijuana Stock Movers For May 14, 2025 - Cannabix Technologies (OTC:BLOZF), Blueberries Medical (OTC:BBRRF)

Leafbuyer Techs LBUY shares closed up 58.05% at $0.03 Greenlane Hldgs GNLN shares closed up 13.21% at $0.01 Blueberries Medical BBRRF shares closed up 9.66% at $0.01 EnWave NWVCF shares closed up 7.78% at $0.25 Zoned Properties ZDPY shares closed up 7.68% at $0.42

Original reporting
Benzinga · Benzinga Insights
Published May 14, 2025, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 15, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Marijuana Stock Movers For May 14, 2025 - Cannabix Technologies (OTC:BLOZF), Blueberries Medical (OTC:BBRRF) — source image
Decision brief

The 30-second read

$GNLNBullishMed
01

Why it matters

The recent price surges reflect positive sentiment but may also be driven by speculative trading. Technical and fundamental analysis should be employed for confirmation.

02

Market read

The sector is currently experiencing bullish sentiment, driven by positive news and investor enthusiasm, which may lead to increased trading activity and sector valuation uplift.

03

What to watch

Potential regulatory changes, sector saturation, or macroeconomic factors could impact the sustainability of current momentum.

Timing: Immediate to short-term

Background

The cannabis sector has experienced increased investor interest due to sector developments, legalization trends, and company-specific news.

Company-level read

Ticker impact

$GNLNBullishMedium confidence
Context

Moderate relevance; shares closed up 13.21%, indicating positive sentiment but less dramatic movement.

Expected impact

Possible short-term upward movement, but with increased volatility due to moderate price change.

Evidence & confidence

The positive price action suggests momentum, but the smaller increase warrants caution. Technical analysis would be beneficial for precise timing.

$ZDPYBullishMedium confidence
Context

Moderate relevance; Zoned Properties shares rose 7.68%, indicating sector interest.

Expected impact

Potential for continued short-term gains, with caution advised due to moderate move.

Evidence & confidence

The upward movement indicates interest, but technical analysis is recommended for timing.

Market effects

The sector shows strong bullish momentum, which may attract additional investor interest and capital inflows.

Primarily affecting North American cannabis and biotech markets, with potential spillover to global markets.

Moderate; sector-specific developments could influence global cannabis industry sentiment.

Counterpoint

The recent surge may be a short-term correction or speculative bubble; caution is advised before committing significant capital.

Key entities

  • Cannabix Technologies

    A cannabis industry technology company involved in developing drug detection devices.

  • Blueberries Medical

    A medical cannabis company operating in multiple jurisdictions.

  • Greenlane Holdings

    A distributor and manufacturer of cannabis accessories and products.

  • EnWave

    A company specializing in dehydration technology for the food, biotech, and cannabis industries.

  • Zoned Properties

    A real estate development company focused on cannabis-related properties.

Related articles

$GNLNMed

Greenlane Holdings, Inc. (GNLN): Results of Operations and Financial Condition

Greenlane Holdings, Inc. (GNLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 August 14, 2026 Greenlane Reports Second Quarter 2026 Financial Results ● Total Operating Expenses Reduced Approximately 37% Sequentially in the Second Quarter 2026 from the First Quarter 2026, Reflecting Continued Cost Alignment ● BERA H

$ZDPYLow

Zoned Properties, Inc. (ZDPY): Results of Operations and Financial Condition

Zoned Properties, Inc. (ZDPY) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001279620 0001279620 2026-08-14 2026-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report

$GNLNMed

Berachain Activates PoL Next; Greenlane Announces Additional Cost-Reduction Initiatives and Reaffirms Long-Term BERA Accumulation Strategy

Greenlane Holdings (Nasdaq: GNLN) reported cost-reduction steps and reiterated its long-term BERA accumulation strategy after aligning expenses with its digital-asset treasury model. It said it reduced headcount to 13 from 23 and cut cost of sales and facility costs. Greenlane also said the Berachain Foundation activated PoL Next to direct more yield to BERA holders; any benefit to Greenlane is uncertain. Greenlane reported holding 81.6M BERA as of July 7, 2026.

$UWMCMed

UWM sued for allegedly misleading investors on hedge strategy

Shareholder Doug Bond filed a class action against UWM Holdings in Michigan federal court, alleging securities fraud over disclosures about UWM’s interest rate derivatives hedge tied to its Two Harbors acquisition. The suit covers purchases from March 9 to Aug. 5, citing a $603.2 million derivatives loss and a $2.05 billion Oaktree cash infusion after a March revenue projection.

$BAMedAI 8/10

Pentagon inks deals with Boeing, RTX to boost production of SM-3 components

The Pentagon signed seven-year framework agreements with Boeing and RTX to expand production of Standard Missile-3 components for SM-3 Block IB and Block IIA, including avionics and ejector assemblies Boeing supplies to Raytheon. The deals aim to stabilize supply chains and expand munitions output. Separately, the Missile Defense Agency awarded Raytheon a $745 million contract for Block IIA interceptors.

$BCLIMed

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics (OTCQB: BCLI) reported Q2 2026 results for the quarter ended June 30, 2026. It said it is preparing to start the Phase 3b ENDURANCE study of NurOwn in ALS under an FDA-agreed Special Protocol Assessment, planning about 200 patients. Cash was about $0.2M vs $1.03M a year earlier, with Q2 net loss about $3.9M. The company appointed Peter J. Pitts as Executive Chairman and raised about $400k in private placements.